Ingenica Solutions raises £4m Series A funding led by CJM Ventures

– UK, Rowland’s Castle – Ingenica Solutions, the leader in helping NHS trusts transform procurement and supply chain processes, today announces that it has successfully raised £4 million in Series A Funding following an over-subscribed investment round. Alongside significant commitments from existing investors, Ingenica Solutions has secured investment from funds associated with CJM Ventures, LLC.

CJM Ventures, LLC is a US based private equity firm that has considerable experience working with young, high growth businesses including those in the healthcare and technology sectors.

The financing comes at a time of rapid growth at Ingenica Solutions, and will support the business as it scales and consolidates its leadership position. Ingenica Solutions continues to accelerate its success with a number of new NHS contract awards in 2018, such as University College London Hospitals NHS Foundation Trust which provides first-class acute and specialist services in five hospitals in central London, and North West Ambulance Service, with further wins expected to be announced shortly.

Dr. Damien Marmion, CEO at Ingenica Solutions said, “CJM Ventures’ support, at this exciting stage for Ingenica, is a strong endorsement of the technology that we deliver for our customers, the quality of our implementations and the prospects for our future. Our market leading technology, in supply chain management and asset tracking, is providing efficiencies at a critical time for healthcare systems around the world.  This new investment provides Ingenica with an opportunity to invest in growth of an expanding market, and in new products and technology for our customers.”

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.